NeuroPace to Present at the Leerink Partners Global Healthcare Conference

NeuroPace, Inc. (Nasdaq: NPCE), a leading medical device company dedicated to improving the lives of individuals with epilepsy, has announced that its management team will present at the esteemed Leerink Partners 2025 Global Healthcare Conference. The presentation is scheduled for January 10, 2025, at 4:20 PM ET (1:20 PM PT) in Miami, FL. In addition to the presentation, the management team will be conducting investor meetings throughout the conference, reinforcing their commitment to engaging with stakeholders and the investment community.

The event will be accessible through a live webcast, providing broader access to the information shared during the presentation. For those unable to attend in real-time, a replay of the webcast will be available for two weeks following the event on NeuroPace’s Investor Relations website.

NeuroPace is renowned for its innovative RNS System, the first and only commercially available brain-responsive platform designed to deliver personalized, real-time treatments directly at the source of seizures. This technology aims to significantly reduce or even eliminate seizures for patients with drug-resistant epilepsy, thus setting a new standard of care. The RNS System symbolizes NeuroPace’s dedication to offering tailored solutions and improved patient outcomes, extending its potential benefits to a broader range of brain disorders.

The company operates from its base in Mountain View, California, and is committed to driving advancement in the treatment of epilepsy and related brain conditions. For investor inquiries, Jeremy Feffer, Managing Director at LifeSci Advisors, can be reached at jfeffer@lifesciadvisors.com. NeuroPace's participation in the Leerink Partners conference underlines its proactive approach to investor engagement and public communication as it continues to pursue its mission in the healthcare landscape.

As NeuroPace, Inc. prepares to present at the Leerink Partners Global Healthcare Conference on January 10, 2025, investors should closely monitor the implications of this event for the company’s stock performance and its positioning within the medical device market focused on epilepsy management.

NeuroPace’s RNS System stands out as an innovative therapeutic solution, being the first brain-responsive platform that addresses drug-resistant epilepsy. This unique selling proposition not only sets the company apart from competitors but signals potential for broader applications in treating other neurological disorders. Given the considerable market size for epilepsy treatments and the ongoing need for advanced medical solutions, the RNS System is crucial for addressing an underserved patient population.

Investors should examine the company's performance metrics in the lead-up to the conference. Key performance indicators, such as revenue growth from RNS System sales, market penetration rates, and feedback from healthcare professionals, will be critical discussion points during the presentation. Additionally, the management team's articulation of strategic partnerships and plans for future product development will provide insights into the long-term viability of NeuroPace.

Market conditions and investor sentiment surrounding healthcare stocks may influence NeuroPace's stock price leading into the conference. As the broader healthcare sector grapples with regulatory changes and shifting payer dynamics, NeuroPace’s focus on providing an innovative, effective solution could lead to increased investor interest.

For investors considering stock positions in NeuroPace, it may be prudent to evaluate trading volatility before and after the January conference. Keeping track of analyst ratings and peer comparisons can offer further guidance on whether to buy, hold, or sell based on the promised insights from the presentation. Accessing the live webcast can also provide real-time insights into the management’s vision and the immediate market reactions.